dn022150+ag (stage ii)
Exocrine Pancreatic Carcinoma
Explore 101 assets in Exocrine Pancreatic Carcinoma →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Jiangxi Kvvit Pharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07656376CT.gov Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Exocrine Pancreatic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| dn022150+ag (stage ii) (this asset) | Jiangxi Kvvit Pharmaceutical Co., Ltd. | P2/3 | CCC · 55 |
| Fluorouracilum | Northwestern University | P2/3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2/3 | BBB |
| Oxaliplatin | OHSU Knight Cancer Institute | P2/3 | BBB |
| Capecitabine | Zhejiang University | P2 | BB |
| Vismodegib | OHSU Knight Cancer Institute | P2 | BB |
| Vinorelbine Ditartrate | OHSU Knight Cancer Institute | P2 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Exocrine Pancreatic Carcinoma cohort
Other indications for dn022150+ag (stage ii)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neoplasm | — | P2/3 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. dn022150+ag (stage ii) in Exocrine Pancreatic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dn022150ag-stage-ii-exocrine-pancreatic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →